NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The program is supported by a grant from the Children's Cancer Research Fund (CCRF) to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research project addresses a fundamental challenge in treating malignant brain tumors: achieving and maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) allows drugs to bypass the blood-brain barrier through direct intracranial infusion, therapeutic benefit can be limited by rapid drug clearance from the treatment site. The Mayo Clinic team will evaluate a combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure after localized delivery. The project will begin with large animal studies and may expand to human studies if successful.
The study will utilize NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach enables targeted therapy while providing real-time physiologic monitoring throughout treatment, offering investigators insight into drug delivery and its effects on the surrounding neural environment. The CCRF award represents a milestone in advancing this therapeutic approach toward clinical evaluation.
The collaboration expands NeuroOne's growing portfolio of drug delivery initiatives and reflects increasing interest from leading academic investigators and biopharmaceutical companies in the company's drug delivery platform. David Wambeke, Chief Business Officer of NeuroOne, said, "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording. We are honored to support Mayo Clinic's efforts to develop new treatment options for children facing these devastating brain tumors."
NeuroOne Medical Technologies Corporation focuses on improving surgical care for neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures while improving patient outcomes. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information is available at nmtc1.com.
This press release includes forward-looking statements subject to risks and uncertainties. For details, refer to NeuroOne's filings with the Securities and Exchange Commission.
